Coronavirus disease 2019 (COVID-19) is a life-threatening respiratory illness resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. As of mid-March 2020, there have been over 175 000 cases worldwide spanning six continents and at least 67 countries \[[@R1]\]. While epidemiological and clinical characteristics of COVID-19 have been described, we still lack information regarding the risk factors for mortality.

In studies thus far, hypertension is present in 23--30% of patients requiring hospital admission for management of COVID-19. A retrospective, multicenter cohort study published in *Lancet* found hypertension to be the most common comorbidity among patients with COVID-19. Of 191 patients with COVID-19 in their study, 58 (30%) had a past medical history of hypertension. This is unsurprising given the general prevalence of hypertension. However, among other comorbidities such as diabetes, chronic obstructive lung disease, and chronic kidney disease, hypertension was most significantly associated with mortality (*P* = 0.0008). Only coronary heart disease was found to be more statistically significant in its association with mortality (*P* \< 0.0001) \[[@R2]\].

A potential mechanism to explain hypertension\'s link with increased mortality involves the viral mode of entry. It is understood that SARS-CoV-2 binds angiotensin-converting enzyme 2 (ACE2) on type II pneumocytes in the lungs. Human ACE2 appears to be both necessary and sufficient for SARS-CoV entry \[[@R3]\]. ACE2 is a monocarboxypeptidase known for cleaving substrates as part of the renin--angiotensin system. ACE2 functions diffusely across epithelia to indirectly maintain systemic blood pressure. However, its levels are inherently low in the lungs \[[@R4]\]. Consequently, soluble ACE2 may be used to competitively intercept SARS-CoV-2 and prevent viral entry at the respiratory epithelium.

Currently, ACE2 expression in patients with COVID-19 is poorly understood. For one, baseline RNA expression of ACE2 in type II pneumocytes varies across ethnicities \[[@R5]\]. Second, the expression of ACE2 is increased in those with certain medical conditions (e.g. type I or type II diabetes mellitus) or in those being treated with ACE inhibitors, angiotensin II type I receptor blockers (ARBs), thiazolidinediones, and ibuprofen \[[@R6]\]. Upregulated ACE2 levels may predispose to COVID-19 by increasing potential sites for viral binding and entry. However, the evidence to support this claim remains unsubstantiated in human trials.

Given this theoretical risk, further studies should specify medication use in COVID-19-infected patients. To date, governing bodies such as the European Society of Cardiology do not recommend discontinuation of ACE inhibitor or ARBs treatment. Regardless, it may be useful to clarify whether hypertension acts directly or indirectly to portend increased mortality in patients with COVID-19. In the time being, recombinant ACE2 should be evaluated in animal and human studies to determine its effectiveness in attenuating SARS-CoV-2 infection.
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